Literature DB >> 8411395

Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

N K Back1, L Smit, M Schutten, P L Nara, M Tersmette, J Goudsmit.   

Abstract

Three closely related molecular human immunodeficiency virus type 1 (HIV-1) clones, with differential neutralization phenotypes, were generated by cloning of an NcoI-BamHI envelope (env) gene fragment (HXB2R nucleotide positions 5221 to 8021) into the full-length HXB2 molecular clone of HIV-1 IIIB. These env gene fragments, containing the complete gp120 coding region and a major part of gp41, were obtained from three different biological clones derived from a chimpanzee-passaged HIV-1 IIIB isolate. Two of the viruses thus obtained (4.4 and 5.1) were strongly resistant to neutralization by infection-induced chimpanzee and human polyclonal antibodies and by HIV-1 IIIB V3-specific monoclonal antibodies and weakly resistant to soluble CD4 and a CD4-binding-site-specific monoclonal antibody. The third virus (6.8) was sensitive to neutralization by the same reagents. The V3 coding sequence and the gp120 amino acid residues important for the discontinuous neutralization epitope overlapping the CD4-binding site were completely conserved among the clones. However, the neutralization-resistant clones 4.4 and 5.1 differed from neutralization-sensitive clone 6.8 by two mutations in gp41. Exchange experiments confirmed that the 3' end of clone 6.8 (nucleotides 6806 to 8021; amino acids 346 to 752) conferred a neutralization-sensitive phenotype to both of the neutralization-resistant clones 4.4 and 5.1. From our study, we conclude that mutations in the extracellular portion of gp41 may affect neutralization sensitivity to gp120 antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8411395      PMCID: PMC238140     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1.

Authors:  J P Langedijk; N K Back; P J Durda; J Goudsmit; R H Meloen
Journal:  J Gen Virol       Date:  1991-10       Impact factor: 3.891

3.  Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.

Authors:  P L Nara; W G Robey; L O Arthur; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek; P J Fischinger
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

4.  Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

Authors:  M S Reitz; C Wilson; C Naugle; R C Gallo; M Robert-Guroff
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

5.  Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120.

Authors:  C Thiriart; M Francotte; J Cohen; C Collignon; A Delers; S Kummert; C Molitor; D Gilles; P Roelants; F van Wijnendaele
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

6.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

7.  Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus.

Authors:  D C Montefiori; I Y Zhou; B Barnes; D Lake; E M Hersh; Y Masuho; L B Lefkowitz
Journal:  Virology       Date:  1991-06       Impact factor: 3.616

8.  Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120.

Authors:  R L Willey; E K Ross; A J Buckler-White; T S Theodore; M A Martin
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

9.  Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Thiriart; L Smit; C Bruck; C J Gibbs
Journal:  Vaccine       Date:  1988-06       Impact factor: 3.641

10.  Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease.

Authors:  A Von Gegerfelt; J Albert; L Morfeldt-Månson; K Broliden; E M Fenyö
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

View more
  38 in total

1.  Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Authors:  Wei Wang; Christopher J De Feo; Min Zhuang; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

2.  Oligomeric Structure and Three-Dimensional Fold of the HIV gp41 Membrane-Proximal External Region and Transmembrane Domain in Phospholipid Bilayers.

Authors:  Byungsu Kwon; Myungwoon Lee; Alan J Waring; Mei Hong
Journal:  J Am Chem Soc       Date:  2018-06-22       Impact factor: 15.419

3.  Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.

Authors:  E J Park; L K Vujcic; R Anand; T S Theodore; G V Quinnan
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

4.  Shortening of the symptom-free period in rhesus macaques is associated with decreasing nonsynonymous variation in the env variable regions of simian immunodeficiency virus SIVsm during passage.

Authors:  P J Valli; V V Lukashov; J L Heeney; J Goudsmit
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

5.  Structured-tree topology and adaptive evolution of the simian immunodeficiency virus SIVsm envelope during serial passage in rhesus macaques according to likelihood mapping and quartet puzzling.

Authors:  P J Valli; J Goudsmit
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.

Authors:  E Vicenzi; D S Dimitrov; A Engelman; T S Migone; D F Purcell; J Leonard; G Englund; M A Martin
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes.

Authors:  Adam S Dingens; Dana Arenz; Haidyn Weight; Julie Overbaugh; Jesse D Bloom
Journal:  Immunity       Date:  2019-01-29       Impact factor: 31.745

9.  Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.

Authors:  S Gnanakaran; Marcus G Daniels; Tanmoy Bhattacharya; Alan S Lapedes; Anurag Sethi; Ming Li; Haili Tang; Kelli Greene; Hongmei Gao; Barton F Haynes; Myron S Cohen; George M Shaw; Michael S Seaman; Amit Kumar; Feng Gao; David C Montefiori; Bette Korber
Journal:  PLoS Comput Biol       Date:  2010-10-07       Impact factor: 4.475

10.  Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.

Authors:  Cleo G Anastassopoulou; Thomas J Ketas; Per Johan Klasse; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.